TransMedics Completes Asset Acquisition/Disposition on Dec 29

TL;DR

**TMDX completed an asset deal on Dec 29, 2023, signaling a shift in its business.**

AI Summary

TransMedics Group, Inc. (TMDX) filed an 8-K on January 2, 2024, confirming the completion of an acquisition or disposition of assets on December 29, 2023. This filing, under Item 2.01, signals a change in the company's asset structure, which could impact future revenue streams or operational costs. Investors should understand the specifics of this transaction as it may affect TMDX's financial performance and strategic direction going forward.

Why It Matters

This filing indicates a significant change in TransMedics' asset base, which could alter its financial health, operational capabilities, and competitive position. Investors need to understand the nature of this transaction to assess its potential impact on the company's future growth and profitability.

Risk Assessment

Risk Level: medium — The filing indicates a completed transaction without disclosing details, creating uncertainty about its financial impact and strategic implications.

Analyst Insight

Investors should monitor TransMedics' upcoming financial reports for detailed information regarding the completed asset transaction to understand its financial implications and strategic rationale. Without further details, it's difficult to assess the full impact.

Key Players & Entities

• TransMedics Group, Inc. (company) — the registrant filing the 8-K
• December 29, 2023 (date) — date of the earliest event reported
• January 2, 2024 (date) — date the 8-K was filed
• 001-38891 (other) — Commission File Number for TransMedics Group, Inc.
• TMDX (other) — trading symbol for TransMedics Group, Inc.

Forward-Looking Statements

• TransMedics will provide more details about the completed acquisition or disposition in its next quarterly or annual report. (TransMedics Group, Inc.) — high confidence, target: Q1 2024 Earnings Report
• The completed transaction will lead to a re-evaluation of TransMedics' market valuation by analysts. (TransMedics Group, Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $12.7 m — acquire the aircraft was approximately $12.7 million, inclusive of an amount previousl

Filing Documents

• d524685d8k.htm (8-K) — 23KB
• 0001193125-24-000684.txt ( ) — 138KB
• tmdx-20231229.xsd (EX-101.SCH) — 3KB
• tmdx-20231229_lab.xml (EX-101.LAB) — 17KB
• tmdx-20231229_pre.xml (EX-101.PRE) — 11KB
• d524685d8k_htm.xml (XML) — 3KB

01

Item 2.01. Completion of Acquisition or Disposition of Assets. As previously disclosed in a Current Report on Form 8-K filed by TransMedics Group, Inc. (the "Company") on September 5, 2023, a Current Report on Form 8-K filed by the Company on September 12, 2023, a Current Report on Form 8-K filed by the Company on September 22, 2023, a Current Report on Form 8-K filed by the Company on November 13, 2023 and a Current Report on Form 8-K filed by the Company on December 19, 2023 (together, the "Prior Reports"), TransMedics, Inc. (the "Buyer"), a Delaware corporation and wholly-owned subsidiary of the Company, acquired ten fixed-wing aircraft (collectively, the "Prior Acquisitions") as more specifically described in the Prior Reports. Subsequently, on December 29, 2023, the Buyer acquired a fixed-wing aircraft from Embraer Executive Aircraft, Inc. (together with the Prior Acquisitions, the "Acquisitions"). The aggregate purchase price paid by the Buyer to acquire the aircraft was approximately $12.7 million, inclusive of an amount previously paid to a third party. The Company intends to use each of the 11 aircraft it has acquired to date to transport donor organs as part of the services offered under the Company's National OCS Program, and for purposes of this Current Report on Form 8-K the Company considers the Acquisitions to be a series of related transactions with respect to the acquisition of a fleet of aircraft for use in the Company's National OCS Program.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRANSMEDICS GROUP, INC. Date: January 2, 2024 By: /s/ Stephen Gordon Name: Stephen Gordon Title: Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR